Navigation Links
Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer
Date:4/20/2009

- Wiggins Joins from Biogen Idec -

SAN DIEGO, April 20 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced that Mark Wiggins has joined the company as Chief Business Officer. Mr. Wiggins comes to Mpex from Biogen Idec, Inc. where he most recently served as Executive Vice President of Business Development, and was a member of the Executive Committee. At Mpex he will be focusing on commercial planning and business development activities related to the company's lead product, MP-376. MP-376 is an inhaled antibiotic which is being developed for use as a maintenance therapy for the prevention of exacerbations in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD).

During his 11 years at Biogen Idec and its predecessor Idec Pharmaceuticals, Mr. Wiggins was involved in a wide variety of commercial and business development activities. As Vice President of Marketing and Business Development at Idec he was responsible for all aspects of marketing and reimbursement. He was also a member of the management committee for the collaboration with Genentech on Rituxan(R), a drug generating multi-billions of dollars annually and used for treating a number of cancer and autoimmune indications. As global head of business development for Biogen Idec, Mr. Wiggins and his team completed three acquisitions and more than 20 licensing/partnering transactions. Prior to his time with Biogen Idec, Mr. Wiggins held a number of senior positions in marketing and business development for Hybridon, Schering-Plough, Johnson&Johnson and Pfizer. Mr. Wiggins received his B.S. degree in finance from Syracuse University and an MBA from the University of Arizona.

"Mark's background in the industry spearheading highly successful deals and partnerships is impressive and we are delighted to have him join Mpex," said Daniel Burgess, President and Chief Executive Officer of Mpex P
'/>"/>

SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
2. Sunesis Pharmaceuticals Receives NASDAQ Notification
3. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
4. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
5. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
6. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
7. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
8. Marinus Pharmaceuticals Raises $20 Million in Series B Financing
9. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
10. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
11. Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015 GliaCure, ... of novel therapies for neurological and neuropsychiatric disorders ... initiated dosing of Alzheimer,s patients in a Phase ... GC021109, a compound developed as a potential disease-modifying ... is innovative in that it both promotes the ...
(Date:5/4/2015)... TORONTO , May 4, 2015 /PRNewswire/ - ... pleased to announce the appointment of Dr. Roger ... extensive experience guiding biotech companies in matters including ... Fluorinov,s leadership team and adds significant regulatory expertise ... Dr. Garceau brings 30 years of pharmaceutical ...
(Date:5/4/2015)... Genedata, a leading provider of advanced ... research, today announced the release of Genedata ... enterprise solution for biologics R&D. This first-in-class workflow ... and development of novel biotherapeutics. Version 5.0 enables ... optimization and developability requirements. Genedata will present highlights ...
(Date:5/4/2015)... -- China Cord Blood Corporation (NYSE: CO ) ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Golden ... Kong listed company and a substantial shareholder ... "Agreement") to purchase the Company,s outstanding 7% senior convertible ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3
... 18 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ... Society of Clinical Oncology (ASCO) Annual Meeting being held ... to our product candidates Stimuvax(R), PX-866 and PX-12 are ... Web site, www.abstract.asco.org ., Abstracts ...
... MEDIA ALERTWASHINGTON, May 18 Focusing on ... essential to reducing preventable adverse events, and ... change, influential leaders will gather at the ... to discuss the fundamental shifts necessary to ...
... Paragon Bioservices, Inc., a contract research and manufacturing organization ... Supplier Award for exceptional performance in support of Lilly,s ... in this manner by such an elite organization and ... of quality, excellence and superior customer service in the ...
Cached Biology Technology:Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting 2Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting 3Healthcare Leaders to Address Patient Safety and Reform at the National Patient Safety Foundation Congress, Washington, DC, May 20-22 2Healthcare Leaders to Address Patient Safety and Reform at the National Patient Safety Foundation Congress, Washington, DC, May 20-22 3
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and Markets ... "Face and Voice Biometrics - Global Strategic Business Report" report ... for Face and Voice Biometrics in US$ Thousands by the following ... analytics for the US, Canada , ... , Middle East & ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... by Johns Hopkins scientists has,found the first clear ... remarkable ability to recognize and respond to a ... of genes whose,only apparent function is to jump ... themselves out of the genetic material, and scientists,have ...
... Fast-track recruitment has begun for a trial to investigate ... the National Institute of Allergy and Infectious Diseases (NIAID), ... today. , Sites in Rochester, NY, Baltimore and Los ... The clinical sites are part of the NIAID-sponsored Vaccine ...
... Roger Brent, President and Director of Research at ... announced today ,the release of a new approach ... 2005 edition of Nature,Biotechnology.,The research article, entitled ... 1.0" (pdf) ,describes MSI's discrete stochastic event simulator, ...
Cached Biology News:Gene sequencing explains bioremediation 'bug' 2Gene sequencing explains bioremediation 'bug' 3NIAID Initiates Trial of Experimental Avian Flu Vaccine 2MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 2MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 3
Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
...
ANTI CORTIS BIN GLOB...
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
Biology Products: